John Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John Ellis has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Stacey Lacoste
Univ Saskatchewan, Dept Vet Microbiol, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada
9 shared publicationsSheryl Gow
Univ Saskatchewan, Western Coll Vet Med WCVM, Dept Large Anim Clin Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada
7 shared publicationsCarrie Rhodes
Departments of Veterinary Microbiology (Ellis, Rhodes, Lacoste), Large Animal Clinical Sciences (Gow), and Small Animal Clinical Sciences (Kong, Musil, Snead), Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4
3 shared publicationsNathan Erickson
Univ Saskatchewan, Western Coll Vet Med, Dept Large Anim Clin Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada
3 shared publicationsKeith West
Univ Saskatchewan, Western Coll Vet Med WCVM, Dept Vet Microbiol, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada
2 shared publicationsNoriko Goji
2 shared publications
Latest Publications
- 1 April 2023
- Vol. 64  (4) , 337-343
SARS coronavirus 2-reactive antibodies in bovine colostrum
Objective To determine if bovine colostrum and sera have antibodies that react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Animals Dairy and beef cattle from North America and Europe, sampled before and after the SARS-CoV-2 pandemic. Procedures Indirect ELISAs using whole bovine coronavirus (BCoV) and SARS- CoV-2; whole SARS-CoV-2 Spike 1, Spike 2, and nucleocapsid proteins; and SARS-CoV- 2-specific nucleocapsid peptide as antigens. Virus neutralization assay for BCoV. Surrogate virus neutralization assay for SARS-CoV-2. Results Antibodies reactive to BCoV were highly prevalent in samples collected from cattle before and after the SARS-CoV-2 pandemic. Antibodies reactive with SARS-CoV- 2 were present in the same samples, and apparently increased in prevalence after the SARS-CoV-2 pandemic. These antibodies had variable reactivity with the spike and nucleocapsid proteins of SARS-CoV-2 but were apparently not specific for SARS-CoV- 2. Conclusions Bovine coronavirus continues to be endemic in cattle populations, as indicated by the high prevalence of antibodies to the virus in colostrum and serum samples. Also, the prevalent antibodies to SARS-CoV-2 in bovine samples, before and after the pandemic, are likely the result of responses to epitopes on the spike and nucleocapsid proteins that are shared between the 2 betacoronaviruses. Cross-reactive antibodies in bovine colostrum could be examined for prophylactic or therapeutic effects on SARS-CoV-2 infections in humans.
- 1 April 2023
- Vol. 64  (4) , 337-343
SARS coronavirus 2-reactive antibodies in bovine colostrum
Objective To determine if bovine colostrum and sera have antibodies that react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Animals Dairy and beef cattle from North America and Europe, sampled before and after the SARS-CoV-2 pandemic. Procedures Indirect ELISAs using whole bovine coronavirus (BCoV) and SARS- CoV-2; whole SARS-CoV-2 Spike 1, Spike 2, and nucleocapsid proteins; and SARS-CoV- 2-specific nucleocapsid peptide as antigens. Virus neutralization assay for BCoV. Surrogate virus neutralization assay for SARS-CoV-2. Results Antibodies reactive to BCoV were highly prevalent in samples collected from cattle before and after the SARS-CoV-2 pandemic. Antibodies reactive with SARS-CoV- 2 were present in the same samples, and apparently increased in prevalence after the SARS-CoV-2 pandemic. These antibodies had variable reactivity with the spike and nucleocapsid proteins of SARS-CoV-2 but were apparently not specific for SARS-CoV- 2. Conclusions Bovine coronavirus continues to be endemic in cattle populations, as indicated by the high prevalence of antibodies to the virus in colostrum and serum samples. Also, the prevalent antibodies to SARS-CoV-2 in bovine samples, before and after the pandemic, are likely the result of responses to epitopes on the spike and nucleocapsid proteins that are shared between the 2 betacoronaviruses. Cross-reactive antibodies in bovine colostrum could be examined for prophylactic or therapeutic effects on SARS-CoV-2 infections in humans.
- Open Access
- 1 September 2022
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 58  (5) , 213-230
2022 AAHA Canine Vaccination Guidelines
These guidelines are an update and extension of previous AAHA peer-reviewed canine vaccination guidelines published in 2017. Vaccination is a cornerstone of canine preventive healthcare and one of the most cost-effective ways of maintaining a dog’s health, longevity, and quality of life. Canine vaccination also serves a public health function by forming a barrier against several zoonotic diseases affecting dogs and humans. Canine vaccines are broadly categorized as containing core and noncore immunizing antigens, with administration recommendations based on assessment of individual patient risk factors. The guidelines include a comprehensive table listing canine core and noncore vaccines and a recommended vaccination and revaccination schedule for each vaccine. The guidelines explain the relevance of different vaccine formulations, including those containing modified-live virus, inactivated, and recombinant immunizing agents. Factors that potentially affect vaccine efficacy are addressed, including the patient’s prevaccination immune status and vaccine duration of immunity. Because animal shelters are one of the most challenging environments for prevention and control of infectious diseases, the guidelines also provide recommendations for vaccination of dogs presented at or housed in animal shelters, including the appropriate response to an infectious disease outbreak in the shelter setting. The guidelines explain how practitioners can interpret a patient’s serological status, including maternally derived antibody titers, as indicators of immune status and suitability for vaccination. Other topics covered include factors associated with postvaccination adverse events, vaccine storage and handling to preserve product efficacy, interpreting product labeling to ensure proper vaccine use, and using client education and healthcare team training to raise awareness of the importance of vaccinations.
- 1 September 2022
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 58  (5) , 213-230
Open Access2022 AAHA Canine Vaccination Guidelines
These guidelines are an update and extension of previous AAHA peer-reviewed canine vaccination guidelines published in 2017. Vaccination is a cornerstone of canine preventive healthcare and one of the most cost-effective ways of maintaining a dog’s health, longevity, and quality of life. Canine vaccination also serves a public health function by forming a barrier against several zoonotic diseases affecting dogs and humans. Canine vaccines are broadly categorized as containing core and noncore immunizing antigens, with administration recommendations based on assessment of individual patient risk factors. The guidelines include a comprehensive table listing canine core and noncore vaccines and a recommended vaccination and revaccination schedule for each vaccine. The guidelines explain the relevance of different vaccine formulations, including those containing modified-live virus, inactivated, and recombinant immunizing agents. Factors that potentially affect vaccine efficacy are addressed, including the patient’s prevaccination immune status and vaccine duration of immunity. Because animal shelters are one of the most challenging environments for prevention and control of infectious diseases, the guidelines also provide recommendations for vaccination of dogs presented at or housed in animal shelters, including the appropriate response to an infectious disease outbreak in the shelter setting. The guidelines explain how practitioners can interpret a patient’s serological status, including maternally derived antibody titers, as indicators of immune status and suitability for vaccination. Other topics covered include factors associated with postvaccination adverse events, vaccine storage and handling to preserve product efficacy, interpreting product labeling to ensure proper vaccine use, and using client education and healthcare team training to raise awareness of the importance of vaccinations.
- 1 July 2022
- Vol. 86  (3) , 218-228
Genealogy of an in-vivo passaged isolate of western Canadian bovine respiratory syncytial virus
Bovine respiratory syncytial virus (BRSV) is a primary respiratory pathogen in calves. Clinical infection with this pathogen has been experimentally modelled to assess vaccine efficacy using a field isolate (Asquith) of BRSV that has been sequentially passaged in vivo in neonatal calves to maintain virulence. The objective of this retrospective cumulative analysis of passages over approximately 20 years was to determine if there have been any changes in the viral genome of this isolate because of this process. Sequence analyses indicated that the Asquith isolate placed genetically in a clade comprising US and some European isolates and a recently described Chinese BRSV isolate (DQ). Furthermore, there were rare changes in bases over time in the N, G, and F gene segments examined when comparing among different passages ranging from 1996 to 2019. These results indicated the absence of significant mutations in the absence of significant adaptive immunological pressure.
- 1 July 2022
- Vol. 86  (3) , 218-228
Genealogy of an in-vivo passaged isolate of western Canadian bovine respiratory syncytial virus
Bovine respiratory syncytial virus (BRSV) is a primary respiratory pathogen in calves. Clinical infection with this pathogen has been experimentally modelled to assess vaccine efficacy using a field isolate (Asquith) of BRSV that has been sequentially passaged in vivo in neonatal calves to maintain virulence. The objective of this retrospective cumulative analysis of passages over approximately 20 years was to determine if there have been any changes in the viral genome of this isolate because of this process. Sequence analyses indicated that the Asquith isolate placed genetically in a clade comprising US and some European isolates and a recently described Chinese BRSV isolate (DQ). Furthermore, there were rare changes in bases over time in the N, G, and F gene segments examined when comparing among different passages ranging from 1996 to 2019. These results indicated the absence of significant mutations in the absence of significant adaptive immunological pressure.
- 1 August 2021
- Vol. 62  (8) , 825-833
All in the family: A comparative look at coronaviruses
Coronaviruses, members of the order Nidovirales, the largest and most complex of the positive-stranded RNA viruses, have been recognized as important causes of disease in veterinary medicine for nearly a century. In contrast, in human medicine, especially until the recent SARS-CoV-2 pandemic, they were unimportant viruses associated with the common cold. This is a brief comparative review of the biology of coronaviral infections emphasizing the commonalities among the various members of the family and considering how the veterinary experience with coronaviruses can inform the response to SARS-CoV-2. Coronaviruses are perhaps best viewed as mutation machines whose genetic sequences can readily change through genetic drift, recombination, and deletions from a large genome. However, to be of clinical concern, variants must have the perfect set of amino acids in the S protein receptor binding domain and in their replication-mediating nonstructural proteins. Extensive experience with veterinary coronaviral vaccines suggests that optimal clinical immunity is a tandem of mucosal and systemic responses induced by a combination of mucosal and parenteral vaccines.
- 1 August 2021
- Vol. 62  (8) , 825-833
All in the family: A comparative look at coronaviruses
Coronaviruses, members of the order Nidovirales, the largest and most complex of the positive-stranded RNA viruses, have been recognized as important causes of disease in veterinary medicine for nearly a century. In contrast, in human medicine, especially until the recent SARS-CoV-2 pandemic, they were unimportant viruses associated with the common cold. This is a brief comparative review of the biology of coronaviral infections emphasizing the commonalities among the various members of the family and considering how the veterinary experience with coronaviruses can inform the response to SARS-CoV-2. Coronaviruses are perhaps best viewed as mutation machines whose genetic sequences can readily change through genetic drift, recombination, and deletions from a large genome. However, to be of clinical concern, variants must have the perfect set of amino acids in the S protein receptor binding domain and in their replication-mediating nonstructural proteins. Extensive experience with veterinary coronaviral vaccines suggests that optimal clinical immunity is a tandem of mucosal and systemic responses induced by a combination of mucosal and parenteral vaccines.
- 1 July 2021
- Vol. 62  (7) , 725-728
Bordetella bronchiseptica-reactive antibodies in Canadian polar bears
Bordetella bronchiseptica is a promiscuous bacterium that infects a variety of species but has not been reported in free-ranging polar bears (Ursus maritimus). Sera from 385 polar bears from the western Hudson Bay region, 1986 to 2017, were tested for reactivity to B. bronchiseptica with enzyme-linked immunosorbent assays using anti- canine IgG and Streptococcus protein G as secondary reagents. Sera from bears had variable reactivity to B. bronchiseptica antigens, and there was no difference among bears that had a history of coming near the town of Churchill, Manitoba, and bears that did not. Although the sources of exposure were not determined, equivalent results in both groups suggest that potential exposure to humans (aside from handling during sampling) and their animals (dogs) was not an important co-factor in sero-positivity to B. bronchiseptica.
- 1 July 2021
- Vol. 62  (7) , 725-728
Bordetella bronchiseptica-reactive antibodies in Canadian polar bears
Bordetella bronchiseptica is a promiscuous bacterium that infects a variety of species but has not been reported in free-ranging polar bears (Ursus maritimus). Sera from 385 polar bears from the western Hudson Bay region, 1986 to 2017, were tested for reactivity to B. bronchiseptica with enzyme-linked immunosorbent assays using anti- canine IgG and Streptococcus protein G as secondary reagents. Sera from bears had variable reactivity to B. bronchiseptica antigens, and there was no difference among bears that had a history of coming near the town of Churchill, Manitoba, and bears that did not. Although the sources of exposure were not determined, equivalent results in both groups suggest that potential exposure to humans (aside from handling during sampling) and their animals (dogs) was not an important co-factor in sero-positivity to B. bronchiseptica.
- 1 March 2021
- Vol. 62  (3) , 233-239
Passive transfer of colostral leukocytes: A benefit/risk analysis
Passive immunity is a requirement for survival of conventionally reared domestic animals. Maternal antibody is recognized as the primary effector mechanism of protection of the neonate. There is interest, especially in bovine medicine, in the maternal leukocytes that are also transferred in colostrum. These leukocytes are thought to somehow aid in the development of the neonatal immune system and participate in cellular immune reactions in the neonate, although the means by which this is accomplished is unknown. The purpose of this article is to review the immunology of this maternal/neonatal interaction, and on that basis, evaluate the practical benefits and risks of assuring passive transfer of colostral leukocytes.
- 1 March 2021
- Vol. 62  (3) , 233-239
Passive transfer of colostral leukocytes: A benefit/risk analysis
Passive immunity is a requirement for survival of conventionally reared domestic animals. Maternal antibody is recognized as the primary effector mechanism of protection of the neonate. There is interest, especially in bovine medicine, in the maternal leukocytes that are also transferred in colostrum. These leukocytes are thought to somehow aid in the development of the neonatal immune system and participate in cellular immune reactions in the neonate, although the means by which this is accomplished is unknown. The purpose of this article is to review the immunology of this maternal/neonatal interaction, and on that basis, evaluate the practical benefits and risks of assuring passive transfer of colostral leukocytes.
- 1 July 2020
- Vol. 84  (3) , 163-171
Infection of calves with in-vivo passaged bovine parainfluenza-3 virus, alone or in combination with bovine respiratory syncytial virus and bovine coronavirus
Bovine respiratory disease complex is etiologically complex and usually involves co-infection by several agents, including bovine parainfluenza virus-3 (BPIV-3), bovine respiratory syncytial virus (BRSV), and bovine coronavirus (BCoV). Traditionally, vaccines have been tested in seronegative calves infected with a single in vitro-passaged agent, often with little disease, resulting in unvaccinated subjects. To overcome the potential problem of attenuation coincident with in vitro culture of the viruses, cocktails of field isolates of BPIV-3s and BCoVs were passaged in the lungs of neonatal colostrum-deprived calves. Lung lavage fluids were used as inocula, alone and in combination with in-vivo passaged BRSV, and aerosolized into a trailer containing conventionally reared 9-week-old weaned Holstein calves with decayed, but still measurable, maternal antibodies. Calves developed acute respiratory disease of variable severity. Upon necropsy, there were characteristic gross and histologic lesions in the respiratory tract, associated immunohistochemically with BPIV-3, BRSV, and BCoV. In-vivo passage of viruses is an alternative to in vitro culture to produce inocula to better study the pathogenesis of infection and more rigorously and relevantly assess vaccine efficacy.
- 1 July 2020
- Vol. 84  (3) , 163-171
Infection of calves with in-vivo passaged bovine parainfluenza-3 virus, alone or in combination with bovine respiratory syncytial virus and bovine coronavirus
Bovine respiratory disease complex is etiologically complex and usually involves co-infection by several agents, including bovine parainfluenza virus-3 (BPIV-3), bovine respiratory syncytial virus (BRSV), and bovine coronavirus (BCoV). Traditionally, vaccines have been tested in seronegative calves infected with a single in vitro-passaged agent, often with little disease, resulting in unvaccinated subjects. To overcome the potential problem of attenuation coincident with in vitro culture of the viruses, cocktails of field isolates of BPIV-3s and BCoVs were passaged in the lungs of neonatal colostrum-deprived calves. Lung lavage fluids were used as inocula, alone and in combination with in-vivo passaged BRSV, and aerosolized into a trailer containing conventionally reared 9-week-old weaned Holstein calves with decayed, but still measurable, maternal antibodies. Calves developed acute respiratory disease of variable severity. Upon necropsy, there were characteristic gross and histologic lesions in the respiratory tract, associated immunohistochemically with BPIV-3, BRSV, and BCoV. In-vivo passage of viruses is an alternative to in vitro culture to produce inocula to better study the pathogenesis of infection and more rigorously and relevantly assess vaccine efficacy.
- 1 December 2019
- Vol. 60  (12) , 1305-1311
Canine IgA and IgA deficiency: Implications for immunization against respiratory pathogens
Immunoglobulin A (IgA) is widely recognized as the important antibody isotype involved in protective responses on mucosal surfaces, where it acts primarily by effectuating immune exclusion of foreign material. Selective IgA deficiency (SIgAD) is the most common immunodeficiency disease in dogs and humans and has consequences for mucosal immunity. This review is a comparative look at the biology of IgA and SIgAD with a focus on how this branch of immunology relates to vaccine selection and efficacy for canine infectious respiratory disease.
- 1 December 2019
- Vol. 60  (12) , 1305-1311
Canine IgA and IgA deficiency: Implications for immunization against respiratory pathogens
Immunoglobulin A (IgA) is widely recognized as the important antibody isotype involved in protective responses on mucosal surfaces, where it acts primarily by effectuating immune exclusion of foreign material. Selective IgA deficiency (SIgAD) is the most common immunodeficiency disease in dogs and humans and has consequences for mucosal immunity. This review is a comparative look at the biology of IgA and SIgAD with a focus on how this branch of immunology relates to vaccine selection and efficacy for canine infectious respiratory disease.
- 1 February 2019
- Vol. 60  (2) , 147-152
What is the evidence that bovine coronavirus is a biologically significant respiratory pathogen in cattle?
Coronaviruses, including bovine coronavirus (BCoV), are etiologically associated with enteric and respiratory disease across a wide range of mammalian and avian species. The role of BCoV in calfhood diarrhea is well-established, but its role in the bovine respiratory disease complex (BRDC) has been controversial. This review re-examines the evidence that BCoV is a significant pathogen in the BRDC.
- 1 February 2019
- Vol. 60  (2) , 147-152
What is the evidence that bovine coronavirus is a biologically significant respiratory pathogen in cattle?
Coronaviruses, including bovine coronavirus (BCoV), are etiologically associated with enteric and respiratory disease across a wide range of mammalian and avian species. The role of BCoV in calfhood diarrhea is well-established, but its role in the bovine respiratory disease complex (BRDC) has been controversial. This review re-examines the evidence that BCoV is a significant pathogen in the BRDC.
- 1 December 2018
- Vol. 59  (12) , 1311-1319
Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus following neonatal mucosal priming of beef calves
Bovine respiratory syncytial virus (BRSV) is the leading cause of viral pneumonia in calves, making young passively immune calves candidates for vaccination, and raising issues concerning boosting of neonatally primed responses. To address this, 18, 2-month-old Angus-cross passively immune beef heifer calves that had been primed at birth with a combination viral intranasal vaccine were administered either a parenteral combination vaccine containing modified-live (MLV) BRSV or a similar vaccine containing inactivated BRSV. At 6 months of age, these calves and 2 controls that received only the MLV at 2 months of age were challenged with BRSV via aerosol. Two calves, 1 control, and 1 MLV-boosted, developed severe respiratory disease and required euthanasia; the remaining calves developed no or mild respiratory disease and recovered. Calves that received the inactivated booster had significantly higher arterial oxygen concentrations on Day 7 after challenge and had anamnestic BRSV-specific IgG and neutralizing antibodies after challenge; the MLV-boosted calves did not. These data suggest that adjuvanted inactivated parenteral BRSV vaccines administered at 2 months of age may provide better boosting for neonatally mucosally primed calves.
- 1 December 2018
- Vol. 59  (12) , 1311-1319
Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus following neonatal mucosal priming of beef calves
Bovine respiratory syncytial virus (BRSV) is the leading cause of viral pneumonia in calves, making young passively immune calves candidates for vaccination, and raising issues concerning boosting of neonatally primed responses. To address this, 18, 2-month-old Angus-cross passively immune beef heifer calves that had been primed at birth with a combination viral intranasal vaccine were administered either a parenteral combination vaccine containing modified-live (MLV) BRSV or a similar vaccine containing inactivated BRSV. At 6 months of age, these calves and 2 controls that received only the MLV at 2 months of age were challenged with BRSV via aerosol. Two calves, 1 control, and 1 MLV-boosted, developed severe respiratory disease and required euthanasia; the remaining calves developed no or mild respiratory disease and recovered. Calves that received the inactivated booster had significantly higher arterial oxygen concentrations on Day 7 after challenge and had anamnestic BRSV-specific IgG and neutralizing antibodies after challenge; the MLV-boosted calves did not. These data suggest that adjuvanted inactivated parenteral BRSV vaccines administered at 2 months of age may provide better boosting for neonatally mucosally primed calves.